- Home
- MITK vs IMAB Comparison
MITK vs IMAB Comparison
Compare MITK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITK
- IMAB
- Stock Information
- Founded
- MITK 1983
- IMAB 2014
- Country
- MITK United States
- IMAB United States
- Employees
- MITK N/A
- IMAB N/A
- Industry
- MITK Computer peripheral equipment
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MITK Technology
- IMAB Health Care
- Exchange
- MITK Nasdaq
- IMAB Nasdaq
- Market Cap
- MITK 457.8M
- IMAB 384.6M
- IPO Year
- MITK N/A
- IMAB 2020
- Fundamental
- Price
- MITK $10.31
- IMAB $3.91
- Analyst Decision
- MITK Strong Buy
- IMAB Strong Buy
- Analyst Count
- MITK 3
- IMAB 5
- Target Price
- MITK $12.17
- IMAB $6.80
- AVG Volume (30 Days)
- MITK 385.2K
- IMAB 2.2M
- Earning Date
- MITK 08-07-2025
- IMAB 11-02-2025
- Dividend Yield
- MITK N/A
- IMAB N/A
- EPS Growth
- MITK N/A
- IMAB N/A
- EPS
- MITK 0.33
- IMAB N/A
- Revenue
- MITK $178,134,000.00
- IMAB N/A
- Revenue This Year
- MITK $4.11
- IMAB N/A
- Revenue Next Year
- MITK $7.57
- IMAB N/A
- P/E Ratio
- MITK $29.80
- IMAB N/A
- Revenue Growth
- MITK 6.98
- IMAB N/A
- 52 Week Low
- MITK $6.93
- IMAB $0.60
- 52 Week High
- MITK $11.78
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- MITK 58.40
- IMAB 47.78
- Support Level
- MITK $9.78
- IMAB $3.20
- Resistance Level
- MITK $10.07
- IMAB $4.64
- Average True Range (ATR)
- MITK 0.28
- IMAB 0.44
- MACD
- MITK 0.01
- IMAB -0.15
- Stochastic Oscillator
- MITK 78.57
- IMAB 32.64
About MITK Mitek Systems Inc.
Mitek Systems Inc is engaged in the development, sale, and service of proprietary software solutions related to mobile imaging. The firm is a software development company with expertise in artificial intelligence, and machine learning. It serves more than 7,900 financial services organizations, financial technology (fintech) brands, telecommunications companies, and marketplace brands across the globe. The company's Mobile Deposit solution is used by consumers for mobile check deposits. The company's Mobile Verify verifies a user's identity online enabling organizations to build safer digital communities, whereas CheckReader enables financial institutions to automatically extract data from a check image received across any deposit channel - branch, ATM, RDC, and mobile.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).